Novo Nordisk (NVO) has released an update.
Novo Nordisk, a leading global healthcare company, has announced a transaction involving the sale of 8,480 shares by a board member, Liselotte Hyveled. The sale took place on August 13, 2024, on Nasdaq Copenhagen, with shares priced at DKK 895.50 each, totaling approximately DKK 7,593,840. This financial activity is part of the company’s regular disclosure in compliance with market abuse regulations.
For further insights into NVO stock, check out TipRanks’ Stock Analysis page.
